I agree Muzarati. If they had a business model where there number 1 focus was on their flue drugs and they had a second business unit where they got hold of good prospects and farmed out for milestone and royalty payments I think that would be OK. Ideally with Relenza and LANI they would have established an international profile, netwroks etc,whereby they could have identifed opportunities in Australia and leveraged their international contacts.Instead they purchased assets in the last 12 months in UK and US (where you would think big pharma would be much better placed to identify opportunities). I have some hope that Jim Fox the relatively new chair might have a bit moe initiative than Peter Cook. i liked his remarks at the last AGM about "getting out there and stirring the pot" Also Damien Lismore (I think thats his name) in senior management seems to have a bit more of an eye on shareholder interests.
BTA Price at posting:
$1.09 Sentiment: Hold Disclosure: Held
